AI Article Synopsis

  • The study highlights the impact of SARS-CoV-2 on lung cancer surgery outcomes during the COVID-19 pandemic, comparing results from before and during the pandemic.
  • The 90-day infection rate for patients who had surgery during the pandemic was 7.3%, slightly higher than 3.5% for those operated on just before it, with mortality during the pandemic linked solely to COVID-19.
  • Despite a rise in infection rates, the overall postoperative complications and demographic characteristics of patients did not significantly differ between the two groups.

Article Abstract

Background: The influence of SARS-CoV-2 on surgery for non-small cell lung cancer needs to be understood to inform clinical decision making during and after the COVID-19 pandemic.

Objective: This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a pandemic epicenter.

Methods: We conducted a retrospective review of a prospective database to identify consecutive patients who underwent lung cancer resection before (January 1, 2020-March 10, 2020, group 1; 57 patients) and during the COVID-19 pandemic (March 11, 2020-June 10, 2020, group 2; 41 patients). The primary end point was the occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary outcome measure was 90-day perioperative morbidity and mortality.

Results: Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 infection rates was 7.3% (3 out of 41) for patients undergoing an operation during the pandemic and 3.5% (2 out of 57) in patients operated on immediately before the pandemic. All patients tested positive 10 to 62 days after the index surgical procedure following hospital discharge. Four COVID-19-positive patients were symptomatic and 4 out of 5 patients required hospitalization, were men, previous or current smokers with hyperlipidemia, and underwent a sublobar resection. Univariate analysis did not identify any differences in postoperative complications before or during the COVID-19 pandemic. Ninety-day mortality was 5% (2 out of 41) for lung cancer surgery performed during the pandemic, with all deaths occurring due to COVID-19, compared with 0% (0 out of 57) mortality in patients who underwent an operation before the pandemic.

Conclusions: During the COVID-19 pandemic, COVID-19 infections occurred in 7.3% of patients who underwent surgery for non-small cell lung cancer. In this series all infections occurred after hospital discharge. Our results suggest that COVID-19 infections occurring within 90 days of surgery portend a 40% mortality, warranting close postoperative surveillance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885108PMC
http://dx.doi.org/10.1016/j.jtcvs.2021.11.092DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
covid-19 pandemic
16
patients underwent
12
patients
10
covid-19
9
cancer surgery
8
pandemic
8
surgery non-small
8
non-small cell
8
cell lung
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!